肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

中国食管癌围手术期免疫治疗专家共识（2021年）

2022-02-28 国家癌症中心食管癌多学科协作组 中华胸部外科电子杂志

消化道肿瘤食管癌免疫治疗

我国是世界范围内的食管癌大国,每年新发病例数约占全球总患者数的一半。食管癌也是我国常见上消化道恶性肿瘤之一,据统计我国每年食管癌发病率及病死率分别位列所有恶性肿瘤的第6位及第4位,严重危害我国人民健康

中文标题：

中国食管癌围手术期免疫治疗专家共识（2021年）

发布机构：

国家癌症中心食管癌多学科协作组

发布日期：

2022-02-28

简要介绍：

我国是世界范围内的食管癌大国,每年新发病例数约占全球总患者数的一半。食管癌也是我国常见上消化道恶性肿瘤之一,据统计我国每年食管癌发病率及病死率分别位列所有恶性肿瘤的第6位及第4位,严重危害我国人民健康。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国食管癌围手术期免疫治疗专家共识（2021年）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ae3e41c0023e65b7, title=中国食管癌围手术期免疫治疗专家共识（2021年）, enTitle=, guiderFrom=中华胸部外科电子杂志, authorId=0, author=, summary=我国是世界范围内的食管癌大国,每年新发病例数约占全球总患者数的一半。食管癌也是我国常见上消化道恶性肿瘤之一,据统计我国每年食管癌发病率及病死率分别位列所有恶性肿瘤的第6位及第4位,严重危害我国人民健康, cover=https://img.medsci.cn/2022310/1646892249708_5579292.jpg, journalId=0, articlesId=null, associationId=2501, associationName=国家癌症中心食管癌多学科协作组, associationIntro=国家癌症中心食管癌多学科协作组, copyright=0, guiderPublishedTime=Mon Feb 28 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">我国是世界范围内的食管癌大国,每年新发病例数约占全球总患者数的一半</span><span style="color: #666666;">。食管癌也是我国常见上消化道恶性肿瘤之一,据统计我国每年食管癌发病率及病死率分别位列所有恶性肿瘤的第6位及第4位</span><span style="color: #666666;">,严重危害我国人民健康。&nbsp;</span></p>, tagList=[TagDto(tagId=439, tagName=消化道肿瘤), TagDto(tagId=751, tagName=食管癌), TagDto(tagId=1246, tagName=免疫治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4360, appHits=182, showAppHits=0, pcHits=555, showPcHits=4177, likes=1, shares=86, comments=6, approvalStatus=1, publishedTime=Thu Mar 10 15:43:00 CST 2022, publishedTimeString=2022-02-28, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Mar 10 13:46:36 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Wed Jan 03 08:29:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国食管癌围手术期免疫治疗专家共识（2021年）.pdf)])
中国食管癌围手术期免疫治疗专家共识（2021年）.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202215, encodeId=4e0a12022152d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=杨海东, createdTime=Sun Mar 13 14:14:45 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201898, encodeId=3ec4120189895, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=445d6548438, createdName=ms5000000939043801, createdTime=Sat Mar 12 08:33:16 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201738, encodeId=94101201e3822, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 16:47:29 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201652, encodeId=2cd61201652cc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6624868252, createdName=740168980, createdTime=Fri Mar 11 10:35:43 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201634, encodeId=a99a1201634cd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/81A938BD7B7092A7CCA2C342535D654F/100, createdBy=42012373285, createdName=juliahuang, createdTime=Fri Mar 11 09:41:34 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-13 杨海东

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202215, encodeId=4e0a12022152d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=杨海东, createdTime=Sun Mar 13 14:14:45 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201898, encodeId=3ec4120189895, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=445d6548438, createdName=ms5000000939043801, createdTime=Sat Mar 12 08:33:16 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201738, encodeId=94101201e3822, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 16:47:29 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201652, encodeId=2cd61201652cc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6624868252, createdName=740168980, createdTime=Fri Mar 11 10:35:43 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201634, encodeId=a99a1201634cd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/81A938BD7B7092A7CCA2C342535D654F/100, createdBy=42012373285, createdName=juliahuang, createdTime=Fri Mar 11 09:41:34 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-12 ms5000000939043801

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202215, encodeId=4e0a12022152d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=杨海东, createdTime=Sun Mar 13 14:14:45 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201898, encodeId=3ec4120189895, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=445d6548438, createdName=ms5000000939043801, createdTime=Sat Mar 12 08:33:16 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201738, encodeId=94101201e3822, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 16:47:29 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201652, encodeId=2cd61201652cc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6624868252, createdName=740168980, createdTime=Fri Mar 11 10:35:43 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201634, encodeId=a99a1201634cd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/81A938BD7B7092A7CCA2C342535D654F/100, createdBy=42012373285, createdName=juliahuang, createdTime=Fri Mar 11 09:41:34 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-11 ms7000001031705413

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202215, encodeId=4e0a12022152d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=杨海东, createdTime=Sun Mar 13 14:14:45 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201898, encodeId=3ec4120189895, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=445d6548438, createdName=ms5000000939043801, createdTime=Sat Mar 12 08:33:16 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201738, encodeId=94101201e3822, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 16:47:29 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201652, encodeId=2cd61201652cc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6624868252, createdName=740168980, createdTime=Fri Mar 11 10:35:43 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201634, encodeId=a99a1201634cd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/81A938BD7B7092A7CCA2C342535D654F/100, createdBy=42012373285, createdName=juliahuang, createdTime=Fri Mar 11 09:41:34 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-11 740168980

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202215, encodeId=4e0a12022152d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=杨海东, createdTime=Sun Mar 13 14:14:45 CST 2022, time=2022-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201898, encodeId=3ec4120189895, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=445d6548438, createdName=ms5000000939043801, createdTime=Sat Mar 12 08:33:16 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201738, encodeId=94101201e3822, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce496545404, createdName=ms7000001031705413, createdTime=Fri Mar 11 16:47:29 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201652, encodeId=2cd61201652cc, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6624868252, createdName=740168980, createdTime=Fri Mar 11 10:35:43 CST 2022, time=2022-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201634, encodeId=a99a1201634cd, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/81A938BD7B7092A7CCA2C342535D654F/100, createdBy=42012373285, createdName=juliahuang, createdTime=Fri Mar 11 09:41:34 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-11 juliahuang

    学习学习

    0

相关指南

国际癌症报告合作组织 (ICCR) 的建议：结直肠癌病理报告数据集

国际癌症报告合作组织 (ICCR) · 2022-03-01

2022 AGA 肝细胞癌全身治疗临床实践指南

美国胃肠病协会(AGA,American Gastroenterological Association) · 2022-03-01

2021V1美国国家综合癌症网络胃肠间质瘤诊疗指南更新解读

华中科技大学同济医学院附属协和医院胃肠外科 · 2022-01-20

2022 CCO循证指南：结直肠癌治愈性治疗后患者的监测

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2022-01-30

中国家族遗传性肿瘤临床诊疗专家共识（2021年版）（4）——家族遗传性结直肠癌

中国抗癌协会家族遗传性肿瘤专业委员会 · 2022-01-15

《中国结直肠癌癌前病变和癌前状态处理策略专家共识》解读

海军军医大学附属长海医院消化内科 · 2022-01-20